Elicio Therapeutics, Inc. Operating Income (Loss) in USD from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Elicio Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2025.
  • Elicio Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$8.05M, a 22.2% increase year-over-year.
  • Elicio Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$42.3M, a 3.54% decline year-over-year.
  • Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$45M, a 25.9% decline from 2023.
  • Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$35.7M, a 50.6% decline from 2022.
  • Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$23.7M, a 39.6% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Elicio Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$42.3M -$8.05M +$2.3M +22.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 -$44.6M -$10.1M +$833K +7.63% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 -$45.5M -$10.7M -$495K -4.83% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 -$45M -$13.5M -$4.09M -43.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 -$40.9M -$10.3M +$427K +3.96% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 -$41.3M -$10.9M -$3.15M -40.5% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 -$38.2M -$10.2M -$2.44M -31.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 -$35.7M -$9.39M -$12.1M -441% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 -$23.6M -$10.8M -$5M -86.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$18.6M -$7.78M -$1.55M -24.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$17.1M -$7.81M +$6.68M +46.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$23.7M $2.75M -$11.9M -81.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$11.9M -$5.77M +$9.99M +63.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$21.8M -$6.23M +$12M +65.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$33.9M -$14.5M +$5.45M +27.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$39.3M $14.6M +$28.5M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-17
Q3 2021 -$67.8M -$15.8M -$4.17M -36% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$63.6M -$18.2M -$975K -5.65% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$62.6M -$19.9M -$7.37M -58.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$55.3M -$13.9M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$11.6M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$17.3M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$12.6M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17

Elicio Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$45M -$9.24M -25.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$35.7M -$12M -50.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$23.7M +$15.6M +39.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$39.3M +$16M +28.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-17
2020 -$55.3M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.